Whitehawk reports Q2 2026 results, HWK-206 trial on track for Q3 start

Whitehawk Therapeutics reported second quarter 2026 results on August 6, 2026, saying its Phase 1 studies for HWK-007 and HWK-016 continued enrollment and the company remained on track to start a Phase 1 trial for HWK-206 in the third quarter.¹ HWK-007 is being tested in patients with non-squamous, EGFR wild-type non-small cell lung cancer, platinum-resistant ovarian cancer, and endometrial cancer, under trial registry number NCT07444814.¹ HWK-016 is being studied in patients with advanced ovarian and endometrial cancers (NCT07470853).¹

The company said HWK-206 is a planned Phase 1 study in small-cell lung cancer and neuroendocrine tumors set to start in the third quarter of 2026, while HWK-007 and HWK-016 continue recruiting, with initial results expected in the first half of 2027.¹

On the pipeline expansion side, Whitehawk entered a new option agreement with Hangzhou DAC covering access to CPT113 for use in up to five additional ADC programs.¹ Under the deal, Whitehawk will pick targets and source antibodies while keeping global rights and full program control over the resulting programs.¹ Separately, the company entered a global collaboration with Biocytogen for bispecific antibody ADC development, under which Biocytogen will provide access to up to five bispecific antibodies from its RenLite platform for Whitehawk to combine with its own linker-payload technology.¹

On financing, Whitehawk said it closed an $87.5 million private placement equity financing in May 2026,¹ with participation from several existing institutional investors and members of its executive team. As of June 30, 2026, the company reported cash, cash equivalents and short-term investments of $190.0 million, up from $145.7 million at the end of 2025, which it said would fund operations into the second half of 2028.¹